Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.

scientific article published on 18 May 2017

Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA. is …
instance of (P31):
erratumQ1348305
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1085438472
P356DOI10.1007/S12325-017-0543-6
P932PMC publication ID5487865
P698PubMed publication ID28523624

P50authorBarnaby HuntQ88105426
P2093author name stringWilliam J Valentine
Jakob Langer
Michelle Mocarski
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue6
P407language of work or nameEnglishQ1860
P921main subjectinsulin glargineQ417317
preproinsulinQ7240673
Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.Q33700904
type 2 diabetesQ3025883
P304page(s)1500-1501
P577publication date2017-06-01
P1433published inAdvances in TherapyQ4686392
P1476titleErratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
P478volume34

Reverse relations

Q33700904Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.corrigendum / erratumP2507

Search more.